BioLineRx (BLRX) Gains from Investment Securities (2014 - 2025)

BioLineRx's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at -$1.1 million for Q4 2025.

• On a quarterly basis, Gains from Investment Securities rose 80.46% year-over-year to -$1.1 million in Q4 2025; TTM through Dec 2025 was -$8.6 million, a 54.66% increase from a year earlier, with the FY2025 full-year figure at -$8.6 million, up 54.66% from the prior year.
• Gains from Investment Securities advanced to -$1.1 million in Q4 2025 per BLRX's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $7.8 million in Q2 2023 and bottomed at -$8.4 million in Q2 2024.
• The 5-year median for Gains from Investment Securities is -$1.1 million (2022), against an average of -$1.0 million.
• Across the five-year window, Gains from Investment Securities surged 1966.75% in 2023 and plunged 246.18% in 2024, its largest moves.
• Year by year, Gains from Investment Securities stood at -$2.2 million in 2021, then plunged by 69.31% to -$3.6 million in 2022, then grew by 20.1% to -$2.9 million in 2023, then tumbled by 85.24% to -$5.4 million in 2024, then jumped by 80.46% to -$1.1 million in 2025.
• Per Business Quant, the three latest BLRX Gains from Investment Securities figures stand at -$1.1 million (Q4 2025), -$1.1 million (Q3 2025), and $1.9 million (Q2 2025).